electroCore reports Q3 EPS (31c), consensus (33c)

Reports Q3 revenue $6.6M, consensus $6.49M. “Demand for our Rx gammaCore and Truvaga solutions continue to drive robust growth,” commented Dan Goldberger, CEO. “Outside of TAC-STIM sales which are inherently variable and incremental to our operations, our business continues showing consistent growth on a quarterly and year to date basis. As we continue to scale, we will generate incremental revenues that will benefit from operating leverage helping us to reach positive cash flow and ultimately drive earnings.”